With the waning COVID caseload in active site loca
Post# of 148292
(Total Views: 433)
Posted On: 05/28/2020 12:03:57 PM
With the waning COVID caseload in active site locations (except UCLA), I'm taking a stab at listing the pros and cons of peeking at the phase 2 trial data. I'm focusing on Mild/Mod since Severe is an obvious choice at 50.
Pros:
-If positive results, can be submitted to FDA for early consideration
-If positive results, could generate publicity to accelerate trial completion and investment
Cons
-if underwhelming results and nothing announced, critics will suspect the worst.
-if submitted to FDA, they could reject and/or negatively alter trial requirements going forward?
Did I miss or misrepresent anything? Also, if CYDY takes a peek, must it be publicly disclosed? I'm just trying to anticipate how the CYDY board of directors will approach this.
Pros:
-If positive results, can be submitted to FDA for early consideration
-If positive results, could generate publicity to accelerate trial completion and investment
Cons
-if underwhelming results and nothing announced, critics will suspect the worst.
-if submitted to FDA, they could reject and/or negatively alter trial requirements going forward?
Did I miss or misrepresent anything? Also, if CYDY takes a peek, must it be publicly disclosed? I'm just trying to anticipate how the CYDY board of directors will approach this.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼